Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

OBJECTIVES: Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumara...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Brenner, Bluma G., Thomas, Réjean, Blanco, José Luis, Ibanescu, Ruxandra-Ilinca, Oliveira, Maureen, Mesplède, Thibault, Golubkov, Olga, Roger, Michel, Garcia, Federico, Martinez, Esteban, Wainberg, Mark A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896408/
https://ncbi.nlm.nih.gov/pubmed/27029845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkw071
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi